US
CA
NZ
UK
AU
IND
Last update at 2025-05-15T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Fagron shareholders approve all voting items AGM
Mon 12 May 25, 05:00 PMFagron publishes agenda for 2025 annual shareholders meeting
Fri 11 Apr 25, 06:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 87.77M | 76.82M | 73.72M | 69.89M | 54.84M |
| Minority interest | -0.45400M | -0.37500M | 4.71M | 4.41M | 3.88M |
| Net income | 69.61M | 61.00M | 59.60M | 41.06M | 42.49M |
| Selling general administrative | - | - | - | 124.69M | 112.57M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 286.17M | 247.50M | 246.73M | 240.02M | 208.28M |
| Reconciled depreciation | 31.30M | 26.48M | 27.48M | 25.96M | - |
| Ebit | 92.41M | 87.07M | 88.56M | 84.11M | 79.22M |
| Ebitda | - | - | - | - | - |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 101.17M | 89.92M | 92.38M | 84.39M | 73.20M |
| Other operating expenses | 0.14M | -1.41200M | 1.61M | 1.89M | 3.08M |
| Interest expense | 10.62M | 8.01M | 10.85M | 12.20M | 0.00000M |
| Tax provision | 17.70M | 15.44M | 13.68M | 14.20M | - |
| Interest income | 4.06M | 1.42M | 0.75M | 1.45M | - |
| Net interest income | -12.48700M | -11.27900M | -13.54900M | -14.41500M | - |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 17.70M | 15.44M | 13.68M | 14.20M | 11.55M |
| Total revenue | 683.88M | 573.81M | 555.97M | 534.70M | 471.68M |
| Total operating expenses | 582.72M | 483.89M | 463.59M | 450.31M | 398.48M |
| Cost of revenue | 397.72M | 326.31M | 309.24M | 294.68M | 263.40M |
| Total other income expense net | - | - | - | -14.50000M | -18.36900M |
| Discontinued operations | - | - | - | -14.14700M | -0.37700M |
| Net income from continuing ops | 70.07M | 61.38M | 60.04M | 55.69M | 43.28M |
| Net income applicable to common shares | 69.61M | 61.00M | 59.60M | 41.06M | 42.49M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1006.95M | 971.01M | 800.42M | 752.83M | 801.24M |
| Intangible assets | 48.56M | 33.63M | 30.67M | 24.51M | 28.81M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | -0.00100M | -0.00100M | - |
| Total liab | 539.33M | 562.38M | 474.95M | 495.01M | 554.80M |
| Total stockholder equity | 463.72M | 402.65M | 320.11M | 253.11M | 242.03M |
| Deferred long term liab | - | - | 7.09M | 6.21M | 6.26M |
| Other current liab | - | 23.19M | 18.88M | 26.30M | 46.55M |
| Common stock | - | 521.24M | 520.78M | 513.99M | 510.14M |
| Capital stock | 524.53M | 521.24M | 520.78M | 513.99M | 510.14M |
| Retained earnings | 206.27M | 150.32M | 95.30M | 47.34M | -6.48600M |
| Other liab | - | 9.11M | 8.62M | 10.30M | 11.77M |
| Good will | 434.36M | 429.77M | 380.41M | 364.65M | 389.33M |
| Other assets | - | 32.73M | 31.35M | 28.34M | 28.02M |
| Cash | 133.01M | 125.34M | 70.65M | 84.25M | 106.68M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 175.26M | 171.01M | 145.06M | 200.26M | 191.77M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 192.03M | 230.80M | 226.74M | 237.09M | 250.05M |
| Short term debt | - | - | - | - | 34.12M |
| Short long term debt | 0.00000M | 9.46M | 6.80M | 64.44M | 34.12M |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | - | -248.19100M | -277.15400M | -289.39700M | -242.80500M |
| Property plant equipment | - | 143.60M | 128.62M | 118.62M | 121.21M |
| Total current assets | 335.90M | 318.01M | 233.71M | 221.88M | 239.19M |
| Long term investments | - | - | - | - | 4.29M |
| Net tangible assets | - | -58.86000M | -83.88100M | -129.85500M | -169.84400M |
| Short term investments | 4.27M | - | - | - | - |
| Net receivables | 62.05M | 84.34M | 72.23M | 57.84M | 55.03M |
| Long term debt | 325.04M | 346.67M | 290.59M | 256.90M | 322.62M |
| Inventory | 113.94M | 108.34M | 90.83M | 79.79M | 77.48M |
| Accounts payable | 104.93M | 97.86M | 83.66M | 72.25M | 77.30M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 671.05M | 653.00M | 566.71M | 530.94M | 562.05M |
| Capital lease obligations | 41.70M | 43.24M | 38.21M | 34.20M | 34.79M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -50.77100M | -11.19200M | -32.87700M | -21.41400M | -38.91700M |
| Change to liabilities | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total cashflows from investing activities | -69.26900M | -31.92300M | -51.29900M | -43.58800M | -54.61100M |
| Net borrowings | 39.88M | -41.64900M | -36.62500M | 16.59M | 27.33M |
| Total cash from financing activities | 13.85M | -61.64800M | -53.11100M | -4.48600M | 1.79M |
| Change to operating activities | -2.14000M | -22.70100M | -10.20900M | -0.11000M | -7.72700M |
| Net income | 69.61M | 61.00M | 59.60M | 41.06M | 42.49M |
| Change in cash | 54.69M | -13.60200M | -22.43700M | 29.11M | 16.81M |
| Begin period cash flow | 70.65M | 84.25M | 106.68M | 77.58M | - |
| End period cash flow | 125.34M | 70.65M | 84.25M | 106.68M | 77.58M |
| Total cash from operating activities | 109.46M | 78.42M | 92.95M | 77.17M | 73.28M |
| Issuance of capital stock | 0.45M | 6.80M | 3.85M | 2.47M | - |
| Depreciation | 35.48M | 23.05M | 23.78M | 22.73M | 13.22M |
| Other cashflows from investing activities | -0.00100M | -0.00100M | -0.00100M | -0.00100M | -0.00100M |
| Dividends paid | -14.57100M | -13.02800M | -5.76600M | -8.60900M | 7.17M |
| Change to inventory | - | - | - | - | 0.00000M |
| Change to account receivables | - | - | - | - | 0.00000M |
| Sale purchase of stock | - | - | - | - | 0.00000M |
| Other cashflows from financing activities | -11.90700M | -13.76900M | -14.56500M | -14.94100M | -18.37100M |
| Change to netincome | 6.51M | 13.63M | 16.08M | 10.27M | 22.28M |
| Capital expenditures | 18.50M | 20.73M | 18.42M | 22.17M | 15.69M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -2.14000M | -22.70100M | -10.20900M | -0.11000M | - |
| Stock based compensation | 1.80M | 3.29M | 1.52M | 1.18M | - |
| Other non cash items | 4.68M | 10.62M | 15.02M | 14.50M | - |
| Free cash flow | 90.96M | 57.69M | 74.53M | 55.00M | - |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ARSUF Fagron NV |
- -% | 20.03 | 17.73 | 15.27 | 1.78 | 2.91 | 1.94 | 10.89 |
| ZTS Zoetis Inc |
2.37 1.48% | 162.72 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.43 1.65% | 25.68 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-8.96 6.39% | 131.25 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.05 0.36% | 14.05 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Venecoweg 20A, Nazareth, Belgium, 9810
| Name | Title | Year Born |
|---|---|---|
| Mr. Rafael Padilla | CEO & Exec. Director | 1978 |
| Ms. Karin de Jong | CFO & Exec. Director | 1979 |
| Ms. Vera Bakker | Chief Operating Officer | 1972 |
| Karen Berg | Global Investor Relations Mang. | NA |
| Mr. Johan Verlinden | Head of Legal, Mergers & Acquisitions | NA |
| Mr. Ivan Jose Marostica | Area Leader Latin America | NA |
| Mr. Andrew C. Pulido | Area Leader North America | NA |
| Mr. Rafael Padilla | CEO & Executive Director | 1978 |
| Ms. Karin de Jong | CFO & Executive Director | 1979 |
| Karen Berg | Global Investor Relations Manager | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...